Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.

Kyunghye BangAndrea Casadei-GardiniChanghoon YooMassimo IavaroneMin-Hee RyuSook Ryun ParkHyung-Don KimYoung-In YoonDong-Hwan JungGil-Chun ParkChul-Soo AhnDeok-Bog MoonShin HwangKi-Hun KimGi-Won SongChiara MazzarelliEleonora AlimentiStephen L ChanMassimo De GiorgioBaek-Yeol RyooSung-Gyu Lee

Published in: Cancer medicine (2022)

Lenvatinib showed consistent efficacy and toxicity profiles in patients with post-LT HCC recurrence that were comparable to those reported from previous studies among non-LT HCC patients. The baseline ALBI grade correlated with better OS in post-LT lenvatinib-treated patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
oxidative stress
patient reported outcomes